Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YPI 011 vs Rabeprazole in Healthy Adults
NCT04703868Phase 1Completed
- Sponsor
- Yungjin Pharm. Co., Ltd.
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ypi-011 in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Yungjin Pharm. Co., Ltd. Primary endpoints: Integrated gastric acidity at Day 28 and Area Under the Curve at steady state (AUCt,ss) at Day 29. Started Jan 2021; status: completed.
02
Drugs
ypi-011
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04703868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703868.